## EPAM: EPAM Systems, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%); PEG 1.37 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($195.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. EPAM Systems Inc. stock underperforms Tuesday when compared to competitors**
- Source: MSN | 20251230T220103 | Somewhat-Bearish | Relevance: 100%
- EPAM Systems Inc. (EPAM) stock recorded losses on Tuesday, underperforming its competitors. The stock closed at $273.74, a decrease of $4.87 (1.75%) from the previous day. This performance places it below the S&P 500's daily gain and indicates a challenging trading day for the company relative to its peers.

**2. EPAM Systems Inc. stock underperforms Tuesday when compared to competitors**
- Source: MarketWatch | 20251230T163000 | Bearish | Relevance: 100%
- EPAM Systems Inc. (EPAM) stock declined by 2.52% on Tuesday, closing at $206.31. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. The stock's fall ended a three-day winning streak.

**3. EPAM Systems, Inc. $EPAM Shares Sold by Norris Perne & French LLP MI**
- Source: MarketBeat | 20251229T123004 | Somewhat-Bullish | Relevance: 100%
- Norris Perne & French LLP MI reduced its stake in EPAM Systems, Inc. (NYSE:EPAM) by 31.7% in the third quarter, selling 37,169 shares and now owning 80,045 shares valued at $12.07 million. The company's board has authorized a $1.00 billion share repurchase program, and insiders have recently sold shares totaling approximately $1.82 million. Several other institutional investors have also adjusted their positions in EPAM, and analysts have issued ratings ranging from "Strong Buy" to "Hold."

**4. Co-Diagnostics stock plunges after announcing 1-for-30 reverse split**
- Source: Investing.com | 20251230T150937 | Somewhat-Bearish | Relevance: 51%
- Co-Diagnostics Inc. (NASDAQ:CODX) stock plummeted 13.8% after the company announced a 1-for-30 reverse stock split. This move is intended to bring Co-Diagnostics into compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will take effect on January 2, 2026, with all outstanding common shares, stock options, and warrants being proportionally adjusted.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.41M) |
| Sells | 5 ($1.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+0.4%)
- Blackrock Inc.: 8.5% (+4.7%)
- Invesco Ltd.: 7.1% (-4.7%)
- Ameriprise Financial: 4.8% (+28.9%)
- State Street Corpora: 4.2% (-0.1%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.37 suggests fair value with growth premium. Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.30). Insider selling cluster ($1.9M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.75 |
| 52W Range | $138.15 - $269.00 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.37 |
| Forward P/E | 16.6 |
| Current P/E | 18.0 |
| YoY Growth | 8.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.5% (minimal 5-day change). Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.21x) but short-term weakness (below SMA20). MACD histogram bearish (-1.35), momentum weakening. RSI neutral at 58. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.53% (CS: 19) | Neutral |
| RSI_14 | 58.3 | Neutral |
| MACD Histogram | -1.35 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.212x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $206.10
- **Stop Loss:** $195.10 (5.3% risk)
- **Target:** $217.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 100
- **Position Value:** $20,610.00
- **Portfolio %:** 20.61%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-19 (Est: $3.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.03 | $3.08 | +1.7% |
| 2025Q2 | $2.61 | $2.77 | +6.0% |
| 2025Q1 | $2.27 | $2.41 | +6.1% |
| 2024Q4 | $2.75 | $2.84 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*